To further strengthen the position of VCO as a possible adjunct therapeutic management for stroke, understanding its effects on classical mediators of inflammation, such as interleukin-1b (IL-1b), interleukin-6 (IL-6), and tumor necrosis factor α (TNFα), should be studied together with studying specific pathways for neurodegeneration and angiogenesis. This evidence concerns the gene IL1B and Stroke.